TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01465139
Drug: CDX-301
Normalized name: CDX-301
DrugBank: CDX-301 (DB19293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDX-301, administered in multiple dosages and frequencies depending on arm:~n=3-6 at between 1-75 μg/kg over 5 days~n=3-6 at 25 μg/kg over 7 days~n=3-6 at 25 μg/kg over 10 days
Study: NCT03069703
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 mg/m2/week for 4 consecutive weeks, at Days 0 ± 2 days, Day 7 ± 2 days, Day 14 ± 2 days and Day 21 ± 2 days, as induction therapy of vasculitis flare, followed by 500 mg-rituximab infusion every 6 months as maintenance therapy, i.e. at Month 6, Month 12 and Month 18
Study: NCT05237115
Drug: Bismuth
Normalized name: Bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: given for 14 days at a dose of colloidal bismuth tartrate capsule 55 mg 4 capsules BID, esomeprazole 40 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.
Study: NCT02656329
Drug: Thyroid blocking
Normalized name: Thyroid
DrugBank: Thyroid, porcine (DB09100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received a thyroid blocking agent before the Iobenguane I-123 Injection, AdreView, scan unless medically not indicated, according to local practice.
Study: NCT03390036
Drug: Triamcinolone Hexacetonide
Normalized name: Triamcinolone Hexacetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone Hexacetonide
Study: NCT00288184
Drug: Allopurinol
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopurinol adminsitered one 200mg capsule by mouth twice daily. Placebo capsule once daily during crossover
Study: NCT01712828
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 25 mg Lenalidomide capsule will be administered orally once in the first period, and once with Quinidine in the second period
Study: NCT01712828
Drug: Quinidine
Normalized name: Quinidine
DrugBank: Quinidine (DB00908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 mg of Quinidine will be administered orally every 12 hours for 1 day followed by 600 mg of Quinidine administered orally every 12 hours for the next 4 consecutive days
Study: NCT01712828
Drug: Temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 25 mg/mL injection of Temsirolimus will be given directly into the vein over 30 minutes once in the second period and once with Lenalidomide in the third period.
Study: NCT01712828
Drug: Diphenhydramine
Normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Just before Temsirolimus is given, 25 mg of Diphenhydramine (Benadryl) will be given directly into the vein to decrease chances of an allergic reaction to Temsirolimus.
Study: NCT03413410
Drug: Metoprolol
Normalized name: Metoprolol
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with acute coronary syndrome take metoprolol during hospital and after discharge in the optimal dosing pathway.
Study: NCT02256774
Drug: BILR 355 BS
Normalized name: BS-001
DrugBank: BS-001 (DB17415)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00434031
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02256774
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00434031
Drug: trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03614403
Drug: vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat-soluble vitamin D injection contain of 300,000 IU vitamin D that given via intramuscular injection
Study: NCT00484471
Drug: aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 15-30 mg/day aripiprazole, 22 weeks
Study: NCT00484471
Drug: valproate
Normalized name: Valproate
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sufficient dose as determined by investigator to maintain the therapeutic level.
Study: NCT02319343
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride (placebo)
Study: NCT02319343
Drug: Isotonic Sodium Chloride
Normalized name: ISOTONIC SODIUM CHLORIDE SOLUTION
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo
Study: NCT03815279
Drug: Carfilzomib
Normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carfilzomib will be administered intravenously three times per cycle (28 day cycles) for cycle 1-12. Thereafter twice per cycle for cycle 13-24
Study: NCT03815279
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide PO once daily on days 1-21 of a 28 day cycle
Study: NCT03815279
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone will be administered weekly
Study: NCT01153217
Drug: Switch from tenofovir to abacavir
DrugBank: Abacavir (DB01048)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Switch from tenofovir to abacavir
Study: NCT01278342
Drug: Sandostatin LAR
Normalized name: Sandostatin LAR
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40 mg intramuscular (i.m.) every 28 days for 3 months
Study: NCT01278342
Drug: pegvisomant
Normalized name: Pegvisomant
DrugBank: Pegvisomant (DB00082)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly doses of pegvisomant 70 mg subcutaneously (s.c.) for 4 months given with Sandostatin LAR 40 mg intramuscular (i.m.) every 28 days for 4 months
Study: NCT01278342
Drug: cabergoline
Normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly cabergoline for 4 months, with weekly doses of Sandostatin LAR 40 mg intramuscular (i.m.) every 28 days for 4 months. Cabergoline doses as follows:~1. st week: 0.25 mg twice a week (0.50 mg/week)~2. nd week: 0.50 mg/week twice a week (1 mg/week)~3. rd week: 0.50 mg four times a week (2 mg/week)~4. th week: 0.50 mg daily (3.5 mg/week) Subsequent 3 months: 0.50 mg daily (3.5 mg/week)
Study: NCT00410631
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00410631
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00410631
Drug: dacarbazine
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00920153
Drug: carmustine
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00920153
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00920153
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00920153
Drug: dacarbazine
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00920153
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally
Study: NCT00410631
Drug: etoposide phosphate
Normalized name: Etoposide Phosphate
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00410631
Drug: ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00410631
Drug: isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00410631
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00410631
Drug: topotecan hydrochloride
Normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00410631
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00410631
Drug: vindesine
Normalized name: vindesine
DrugBank: Vindesine (DB00309)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00920153
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00920153
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00920153
Drug: ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04254822
Drug: Carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol will be started at least 5 days after the index bleeding, unless a contraindication was present. Carvedilol will be start with 6.25 mg once a day and after 3 days increase to 6.25 mg twice-daily (the maximal dose was 12.5 mg/day). Systolic arterial blood pressure should not decrease \<90 mmHg.
Study: NCT00465075
Drug: Bazedoxifene/conjugated estrogens combination
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00920153
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00920153
Drug: methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00920153
Drug: mitoguazone
Normalized name: mitoguazone
DrugBank: Mitoguazone (DB12967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00920153
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00920153
Drug: vindesine
Normalized name: vindesine
DrugBank: Vindesine (DB00309)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT00920153
Drug: vinorelbine tartrate
Normalized name: Vinorelbine Tartrate
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01333423
Drug: Seliciclib
Normalized name: Seliciclib
DrugBank: Seliciclib (DB06195)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose 200 mg by mouth twice daily on Days 1 - 3 of a 28 day cycle.
Study: NCT01425736
Drug: Nimotuzumab and Chemotherapy
Normalized name: cytarabine and daunorubicin
DrugBank: Nimotuzumab (DB06192)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimotuzumab treatment:(200mg/w,18weeks );~Chemotherapy treatment:(Docetaxel(75mg/m²,1 time/21d, 6times);Cisplatin(75mg/m²,1 time/21d, 6 times);Fluorouracil(750mg/m²/d,5times/21d, 30times)Nimotuzumab treatment:(200mg/w,18weeks );
Study: NCT00030368
Drug: bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT00030368
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT01681368
Drug: Birinapant (TL32711)
Normalized name: Birinapant
DrugBank: Birinapant (DB11782)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 47mg/m\^2 intravenous (IV) on days 1, 8 and 15 of each 28 day cycle
Study: NCT02979821
Drug: Poziotinib
Normalized name: Poziotinib
DrugBank: Poziotinib (DB12114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A cycle of study treatment is defined as 28 days.
Study: NCT01057329
Drug: Atomoxetine
Normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mg according to body weight
Study: NCT01057329
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg / die
Study: NCT01057329
Drug: Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5mg 1 wwek and 10 mg from second week
Study: NCT01057329
Drug: Aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5 mg from week 1, 10 mg from week 2
Study: NCT03250689
Drug: Danirixin
Normalized name: Danirixin
DrugBank: Danirixin (DB11922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danirixin will be available as 35 mg oval shaped, white film coated HBr embossed tablets.
Study: NCT03448770
Drug: PEG- 17 gm sachet
Normalized name: PEG
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG- 17 gm sachet 3-4 times per day
Study: NCT03448770
Drug: Lactulose : 20-30gm
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lactulose : 20-30gm
Study: NCT01062802
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 80mg, once a day for four weeks.
Study: NCT00818584
Drug: Micafungin
Normalized name: Micafungin
DrugBank: Micafungin (DB01141)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV Administration
Study: NCT01854749
Drug: S1 combined with cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01545388
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sitagliptin, orally, 50 or 100 mg tablet (continuation of the pre-study dose)
Study: NCT01545388
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin, orally, 500 mg daily (single dose; two 250 mg tablets) for 24 weeks
Study: NCT01545388
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin, orally, 500 mg daily (divided dose; 250 mg tablet b.i.d.) for 24 weeks
Study: NCT01189890
Drug: sitagliptin phosphate
Normalized name: Sitagliptin Phosphate
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sitagliptin tablets, orally, at a dose of 100 mg or 50 mg QD for 30 weeks. The dose level to be administered will depend on the participant's estimated glomerular filtration rate (eGFR), calculated at Visit 3 and may be adjusted as medically indicated during the study.
Study: NCT00754364
Drug: Pemetrexed/Carboplatin
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will receive Pemetrexed intravenous infusion (i.v.) via infusion pump or gravity drip, at a dose of 500 mg/m2 (over a target of 10 minutes). Pemetrexed should be administered every 21 days on the same day.~Patients will receive carboplatin intravenous continuous infusion (i.v.) over 30 minutes via infusion pump or gravity drip, at a dose of AUC5. Carboplatin should be administered every 21 days on the same day.
Study: NCT00754364
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive gemcitabine 1250 mg/m2 as a 30 minutes intravenous infusion on days 1 and 8 and of a 21-day cycle.Patients may continue to receive gemcitabine for up to a maximum of 6 cycles.
Study: NCT01189890
Drug: Glimepiride
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glimepiride tablets, orally, starting at a dose of 1 mg QD, which may be gradually increased, as needed, to maximum dose of 6 mg QD for 30 weeks. The dose may also be decreased as medically indicated during the study.
Study: NCT01189890
Drug: Placebo to Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Matching placebo tablets to sitagliptin to allow for blinding.
Study: NCT01189890
Drug: Placebo to Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Matching placebo tablets to glimepiride to allow for blinding.
Study: NCT02236988
Drug: Apremilast Immediate Release
Normalized name: Apremilast
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 30 mg immediate release tablets
Study: NCT02236988
Drug: Apremilast Modified Release 1
Normalized name: Apremilast
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 75 mg oral tablet of prototype modified release (MR) 1
Study: NCT02236988
Drug: Apremilast Modified Release 2
Normalized name: Apremilast
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 75 mg oral tablet of prototype MR 2
Study: NCT02236988
Drug: Apremilast Modified Release 3
Normalized name: Apremilast
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 75 mg oral capsule of prototype MR 3
Study: NCT02236988
Drug: Apremilast Modified Release 4
Normalized name: Apremilast
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 75 mg oral capsule of prototype MR 4
Study: NCT02236988
Drug: Apremilast Modified Release 5
Normalized name: Apremilast
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 75 mg oral capsule of prototype MR 5
Study: NCT02236988
Drug: Apremilast Modified Release 6
Normalized name: Apremilast
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 75 mg oral capsule of prototype MR 6
Study: NCT02236988
Drug: Apremilast Modified Release 8
Normalized name: Apremilast
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 80 mg oral capsule of prototype MR 8
Study: NCT02236988
Drug: Apremilast Modified Release 9
Normalized name: Apremilast
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 80 mg oral capsule of prototype MR 9
Study: NCT02236988
Drug: Apremilast Modified Release 11
Normalized name: Apremilast
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 80 mg oral capsule of prototype MR 11
Study: NCT02236988
Drug: Apremilast Modified Release 12
Normalized name: Apremilast
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 80 mg oral capsule of prototype MR 12
Study: NCT02236988
Drug: Apremilast Modified Release 13
Normalized name: Apremilast
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 80 mg oral capsule of prototype MR 13
Study: NCT02236988
Drug: Apremilast Modified Release 14
Normalized name: Apremilast
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 80 mg oral capsule of prototype MR 14
Study: NCT03546400
Drug: methylphenidate HCl ERCT
Normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: methylphenidate HCl ERCT
Study: NCT00608868
Drug: Gefitinib
Normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gefitinib tablet 250mg once daily orally
Study: NCT00480935
Drug: Sunitinib Malate (Sutent)
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sutent will be given at 50 mg once daily for 4 consecutive weeks followed by a 1 week washout period. The dosage may change during the cycle due to possible drug toxicities. The nephrectomy will then take place following a one-week washout period.
Study: NCT04006470
Drug: Stannous fluoride dentifrice
Normalized name: Stannous Fluoride
DrugBank: Rice (DB10563)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stannous fluoride (0.454%) dentifrice
Study: NCT04006470
Drug: Positive control dentifrice
Normalized name: sodium fluoride
DrugBank: Rice (DB10563)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Positive control dentifrice containing potassium nitrate or arginine.
Study: NCT04006470
Drug: Negative control dentifrice
Normalized name: sodium fluoride
DrugBank: Rice (DB10563)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Negative control dentifrice containing either sodium fluoride (0.243%) or sodium monofluorophosphate (0.76%)
Study: NCT01451918
Drug: Resveratrol
Normalized name: Resveratrol
DrugBank: Resveratrol (DB02709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500mg bid for one week followed by 1 gram bid for one week prior to lipoprotein study.
Study: NCT02213315
Drug: 100mg Mavrilimumab
Normalized name: Mavrilimumab
DrugBank: Mavrilimumab (DB12534)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg Mavrilimumab
Study: NCT02213315
Drug: 150mg mavrilimumab
Normalized name: Mavrilimumab
DrugBank: Mavrilimumab (DB12534)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150mg mavrilmumab
Study: NCT00437164
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01272908
Drug: rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1000 mg intravenously on Days 1 and 15
Study: NCT00181675
Drug: galantamine HBr
Normalized name: galantamine HBr
DrugBank: Galantamine (DB00674)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01038687
Drug: A3309
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A3390, a bile acid transport inhibitor was provided in either 15 mg or 20 mg oral tablets
Study: NCT03228628
Drug: Fixed 50:50 mixture of nitrous oxide and oxygen
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gaz inhalation will start 5 minutes before the puncture and will be continued until the end of the procedure.
Study: NCT01807221
Drug: Finerenone (BAY94-8862)
Normalized name: Finerenone
DrugBank: Finerenone (DB16165)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01366313
Drug: Paracetamol
Normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: initial doses was 1.5g, with dose adjustment intervals of 0.5g . with maximum dose 2.5 g as an only starting dose / 24 h
Study: NCT01807221
Drug: Inspra (eplerenone)
Normalized name: eplerenone Oral Tablet [Inspra]
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01366313
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Initial of morphine was 5mg, with dose adjustment intervals 1 mg .
Study: NCT01366313
Drug: Paracetamol- Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The initial doses of paracetamol and morphine were 1.5g and 3mg, respectively in the paracetamol-morphine combination group with dose adjustment intervals of 0.25g for paracetamol and 0.5mg for morphine.
Study: NCT00971867
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Solution, I.V., 100 mg/m2 Weekly for 6 of 7 weeks, Until disease progression or unacceptable toxicity became apparent